GlaxoSmithKline (GSK – Egypt) (EGX:BIOC) announced exceptional dividends of EGP 250.543 million, or EGP 3 per share, for the period ended in April 2022, according to a filing to the Egyptian Exchange (EGX) on Wednesday.
It is worth noting that the company’s standalone net profit soared to EGP 929.74 million in January to September from EGP 89.839 million in the same period a year earlier.
GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.
